Streetbeat News

PHRRF

PharmaTher Holdings Ltd

Industry

Pharmaceutical Preparation Manufacturing

Open

0.13

Mkt cap

12M

Volume

10K

High

0.14

P/E Ratio

-4.67

52-wk high

0.32

Low

0.13

Div yield

N/A

52-wk low

0.12

PharmaTher Holdings Ltd. has received an Amendment Acknowledgement Letter from the FDA for its New Drug Application for Ketamine, marking a significant step in the drug's commercialization process.

Portfolio Pulse from

March 11, 2025 | 12:15 pm

PharmaTher Holdings Ltd. has resubmitted a complete response amendment to the FDA for its new drug application for Ketamine, addressing minor deficiencies. The company expects FDA approval by Q2-2025, which could solve the Ketamine shortage and unlock its pharmaceutical potential.

Portfolio Pulse from

March 03, 2025 | 1:15 pm

PharmaTher plans to submit a minor amendment to the FDA's Complete Response Letter by February 2025, aiming for ketamine approval in Q2 2025.

Portfolio Pulse from

February 12, 2025 | 1:15 pm

PharmaTher Holdings Ltd. has granted 800,000 stock options to two of its directors at an exercise price of $0.22 per share. These options vest immediately and have a five-year term. The Chairman and CEO did not receive any options.

Portfolio Pulse from

January 03, 2025 | 10:30 pm

PharmaTher Holdings Ltd. has been granted a post-complete response letter clarification meeting with the FDA regarding their ketamine Abbreviated New Drug Application. This follows a complete response letter issued by the FDA in October 2024.

Portfolio Pulse from

November 13, 2024 | 1:15 pm

The article discusses recent developments in the field of psychedelic therapies for mental health disorders. Small Pharma's (OTC:DMTTF) Phase 1b study on DMT and SSRIs for major depressive disorder (MDD) has released new findings. TheraPsil, a Canadian non-profit, has launched an MDMA-assisted psychotherapy training program. Apex Labs' psilocybin macrodose drug protocol has been approved for a Canadian veteran's treatment-resistant depression. The AdvisorShares Psychedelics ETF (NYSE:PSIL) has been on a slow downtrend. Other companies mentioned include GH Research (NASDAQ:GHRS), COMPASS Pathways (NASDAQ:CMPS), Mind Medicine (NASDAQ:MNMD), Enveric Biosciences (NASDAQ:ENVB), Bright Minds Biosciences (NASDAQ:DRUG), Silo Pharma (NASDAQ:SILO), Atai Life Sciences (NASDAQ:ATAI), FSD Pharma (NASDAQ:HUGE), Incannex Healthcare (NASDAQ:IXHL), Lucy Scientific Discovery (NASDAQ:LSDI), and Cybin Inc. (NYSE:CYBN).

Portfolio Pulse from Lara Goldstein

October 02, 2023 | 1:46 pm

The FDA has accepted PharmaTher Holdings' (OTCQB:PHRRF) new drug application for a racemic ketamine product, KETARX. The goal date for the drug is April 29, 2024. PharmaTher anticipates KETARX’s U.S. commercial launch and the pursuit of international approvals thereafter. The company plans to commercialize KETARX in several dosage forms in the U.S. through its partnership with Vitruvias Therapeutics.

Portfolio Pulse from Lara Goldstein

September 27, 2023 | 6:38 pm

NY-based consulting firm Research Nester predicts the global market for psychedelic substances will grow at a CAGR of around 14% over the next 12 years, reaching $12 billion by 2035. The report features key players such as COMPASS Pathways, Silo Pharma, Numinus Wellness, Cybin, Mind Medicine, PharmaTher Holdings, atai Life Sciences, Jazz Pharmaceuticals, Janssen Pharmaceuticals, and Pfizer. The growth is attributed to increased demand for psychedelic drugs to treat mental health issues, reduced production costs due to the pandemic, and increased investment in R&D.

Portfolio Pulse from Lara Goldstein

September 12, 2023 | 8:35 pm

The Usona Institute has shared positive results from its Phase 2 trial assessing a single 25mg synthetic psilocybin dose for adults with Major Depressive Disorder. COMPASS Pathways (NASDAQ:CMPS) has also shared results from research on its novel AI technologies to support proprietary COMP360 psilocybin treatment for Treatment-Resistant Depression. In the UK, drug policy reform is underway, with a report urging the reclassification of psilocybin mushrooms and other psychedelics to Schedule 2. Several US states are also moving reform bills concerning the study or legalization of psychedelic substances for therapeutic purposes. The AdvisorShares Psychedelics ETF (NYSE:PSIL) opened at $1.79 on September 5, recovering from the prior week’s $1.65.

Portfolio Pulse from Lara Goldstein

September 11, 2023 | 1:34 pm

PharmaTher Holdings (OTCQB:PHRRF) has submitted a priority-original Abbreviated New Drug Application (ANDA) for its proprietary racemic ketamine, KETARX, to the FDA. The company expects an expedited review and anticipates KETARX’s approval and commercial launch in the U.S. in Q2 2024. PharmaTher is also working on international approvals to meet the growing global demand for ketamine. The company is partnering with Vitruvias Therapeutics to commercialize KETARX in the U.S.

Portfolio Pulse from Lara Goldstein

September 06, 2023 | 9:21 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.